"Effect of Screening Using Imaging (CT/ EUS) on Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) in Patients With New Onset Diabetes (NOD)" - A Prospective Pilot Observational Study
NCT ID: NCT06044064
Last Updated: 2023-10-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2023-12-01
2027-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Purpose: To improve the rates of early detection of pancreatic cancer.
Pancreatic ductal adenocarcinoma (PDAC) is a type of cancer that starts in the pancreas, a gland located in your abdomen. It happens when some cells in the pancreas start growing abnormally and form a cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS
NCT05621824
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
NCT04837833
Early Detection Initiative for Pancreatic Cancer
NCT04662879
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT06122896
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
NCT06276764
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
A blood sample for CA 19-9 (cancer detection test)
* A blood sample for CA 19-9 (cancer detection test) levels will be taken at baseline.
* Contrast CT abdomen - Pancreas protocol will be done at baseline.
* EUS (Endoscopic Ultrasound) under moderate sedation will be done at baseline to you.
* If suspicious lesion is found on examination, Fine Needle Aspiration - FNA will be done.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients diagnosed with diabetes based on FBS/ PPBS/ HbA1C
* Presence of atleast 1 FBS parameter measured in the past 6-18 months which was not \> 125 mg/dl
* END-PDAC score \> 2
Exclusion Criteria
* Past history of pancreatic cancer
* History of steroid use
* Contraindications for EUS
50 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asian Institute of Gastroenterology, India
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PDAC-NOD-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.